Engineered Enzymes
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 62/748,668, filed Oct 22, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,604,746 | Engineered Enzymes In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 10,640,754 | Engineered Enzymes In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 10,655,114 | Engineered Enzymes In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 10,876,102 | Engineered Enzymes In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 11,214,781 | Engineered Enzyme In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 12,146,170 | Engineered Enzyme In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 11,345,903 | Engineered Enzymes In force · High confidence | Manus Inscripta, Inc. | In force | High confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.